Shaperon announced that it has successfully expanded its AI platform 'AIDEN' with over ten new candidate discovery algorithms and completed the beta testing phase. With this expansion, Shaperon now possesses the key screening algorithms necessary for the final design of new drug candidates.
Screening algorithms are technologies used to discover candidate substances by predicting their efficacy, toxicity, and pharmacokinetics. Shaperon has continuously enhanced AIDEN’s algorithms, expanding them to include more than ten types, such as efficacy, cytotoxicity, drug absorption, drug distribution, drug metabolism, drug excretion, and drug toxicity.
The R&D team plans to further expand AIDEN's screening algorithms to conduct research on various inflammasomes, including the 'NLRP3' inflammasome, which is currently under study. Shaperon aims to enhance AIDEN by 2025 to enable the design of drug molecular structures using AI technology. Their goal is for AIDEN to identify candidate substances that are highly likely to interact with specific target molecules through molecular dynamics simulations based on AI technology.
A Shaperon representative stated, "With the continuous addition of algorithms, we will be able to drastically reduce the various variables and number of experiments occurring during the lead compound discovery process. This will not only improve the efficiency of research and development but also increase the likelihood of discovering multiple new drug candidates."